Deregulated cell death pathways may lead to the development of cancer, and induction of tumor cell apoptosis is the basis of many cancer therapies. Knowledge accumulated concerning the molecular mechanisms of apoptotic cell death has aided the development of new therapeutic strategies to treat cancer. Signals through death receptors of the tumor necrosis factor (TNF) superfamily have been well elucidated, and death receptors are now one of the most attractive therapeutic targets in cancer. In particular, DR5 and DR4, death receptors of TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), are interesting targets of antibody-based therapy, since TRAIL may also bind decoy receptors that may prevent TRAIL-mediated apoptosis, whereas TRAIL ligand itself selectively induces apoptosis in cancer cells. Here, we review the potential therapeutic utility of agonistic antibodies against DR5 and DR4 and discuss the possible extension of this single-antibody-based strategy when combined with additional modalities that either synergizes to cause enhanced apoptosis or further engage the cellular immune response. Rational design of antibody-based therapies combining the induction of tumor cell apoptosis and activation of tumor-specific adaptive immunity enables promotion of distinct steps of the antitumor immune response, thereby enhancing tumorspecific lymphocytes that can eradicate TRAIL/DR5-resistant mutating, large established and heterogeneous tumors in a manner that does not require the definition of individual tumor-specific antigens.
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Targeting the TNF receptor superfamily in cancer
Programmed cell death (apoptosis) is a controlled cellular mechanism, where the organism maintains cellular homeostasis in normal tissue compartments and eliminates disordered cells (Steller, 1995; Thompson, 1995; Hanahan and Weinberg, 2000; Danial and Korsmeyer, 2004) . Apoptosis can be induced by various stimuli, including growth factor withdrawal, UV light, irradiation or chemicals, and the latter two have been significantly utilized in cancer therapy (Nicholson, 2000; Johnstone et al., 2002) . There are two major signalling pathways leading programmed cell death in mammalian cells: the intrinsic pathway and the extrinsic pathway. The intrinsic pathway is initiated at the mitochondrial level and plays a substantial role in chemotherapy-or irradiation-induced cell death. By contrast, the extrinsic death pathway is initiated through death receptormediated signals on the cell surface (Ashkenazi, 2002) . Cell death induced through the extrinsic pathway has been studied extensively following signals mediated by various members of tumor necrosis factor (TNF) receptor superfamily. The TNF superfamily is characterized by a sequence of two to five cysteine-rich extracellular repeats (Figure 1 ) (Ashkenazi and Dixit, 1998; Ashkenazi, 2002) . The death receptors belonging to the TNF superfamily share a homologous, intracellular death domain of about 80 amino acids, which is essential for the transduction of apoptotic signals (Itoh and Nagata, 1993; Tartaglia et al., 1993) .
Targeting death receptors has been thought a useful approach, since extrinsic pathway alternatively or complementally induces apoptosis in cancer cells as well as the intrinsic pathway-mediated apoptosis in chemotherapeutics and irradiation. CD95, so-called Fas or Apo1, is the best-known death receptor belonging to the TNF receptor superfamily (Schmitz et al., 2000; Timmer et al., 2002) ; however, before long it was appreciated that systemic treatment with Fas-targeting therapy causes severe liver damage (Ogasawara et al., 1993; Galle et al., 1995) . The therapeutic potential of TNFa was also tempered by the demonstration that the systemic administration of recombinant TNFa resulted in a significant systemic toxicity associated with its strong pro-inflammatory activity, including fever, lung or liver failure, increased blood clotting and hypotension (Creaven et al., 1987; Creagen et al., 1988; Hersh et al., 1991; Vassalli, 1992) . Thus, the use of Fas or TNFa receptors as cancer targets appeared fruitless, and more recently efforts have been made to focus on minimizing unfavorable side effects by using local administration, inducible FasL-or TNF-expressing vectors, and tumor targeting gene delivery methods (Kircheis et al., 2002) . Alternatively, the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway is regarded as most promising since apoptosis of tumor cells may be possible without life-threatening toxicity (Ashkenazi, 2002; Smyth et al., 2003; Yagita et al., 2004) .
TRAIL and its receptors
TRAIL was originally identified and cloned based on its sequence homology to the extracellular domain of CD95 ligand (CD95L, FasL) and TNF (Wiley et al., 1995; Pitti et al., 1996) . Like other TNF superfamily members, TRAIL forms homotrimers, which cross link three receptor molecules on the surface of target cells. Although it was reported that TRAIL binds to osteoprotegerin (OPG) (soluble inhibitor of receptor activator of NF-kB (RANK) ligand) at low affinity (Truneh et al., 2000) , TRAIL predominantly interacts with two types of receptors: death receptors triggeringand decoy receptors inhibiting-TRAIL-induced apoptosis (Figure 1) (Ashkenazi, 2002) . To date, four human receptors specific for TRAIL have been identified: the death receptors, DR4 (DR4/TRAIL receptor 1/TRAIL-R1) and DR5 (TRAIL receptor 2/TRAIL-R2/KILL-ER), and the decoy receptors, DcR1/ TRAIL-R3/TRID and DcR2/TRAIL-R4. In mice, there is only one deathinducing receptor, a homolog of human DR5 (mDR5/ mTRAIL-R2), and two decoy receptors (mDcTRAIL-R1/mDcR1 and mDcTRAIL-R2/mDcR2) have been identified to bind mouse TRAIL (Schneider et al., 2003) . Ligation of TRAIL homotrimer to death receptors, DR4 or DR5, induces receptor trimerization leading to the formation of a death-inducing signaling complex. Trimerization of the death domain of the death receptor molecules results in recruitment of the adaptor molecule Fas-associated death domain (FADD), which in turn recruits and activates caspase-8 to execute apoptosis via the extrinsic pathway. In some cell types (type I), activation of caspase 8 is sufficient for subsequent Figure 1 Members of the TNF and TNF receptor superfamily that induce apoptosis. Ligands are shown in their schematic transmembrane form. Arrows indicate receptor interactions with solid lines for strong-affinity binding and dashed lines for low-affinity binding. Dark gray boxes represent receptor cysteine-rich domains and black boxes are cytoplasmic receptor death domains. In humans, TRAIL induces apoptosis via DR5 or DR4. DcR1 with a GPI anchor and DcR2 with a truncated death domain do not trigger an apoptosis signal. TRAF binding motifs (dotted box) in the cytoplasmic region of human DR5 and DcR2 may be responsible for NF-kB activation by these receptors. In mice, TRAIL induces apoptosis via mDR5. mDcR1 with a GPI anchor and two alternative splicing forms of mDcR2 may act decoys. activation of the effector caspase 3 to execute apoptosis (extrinsic pathway). However, in another cell type (type II), amplification through the intrinsic pathway (the mitochondrial pathway) is required (Ashkenazi, 2002; Kelley and Ashkenazi, 2004) . The relative contribution of the extrinsic and intrinsic pathways to TRAILinduced cell death is variable, depending on the cellular context (Figure 2) . In contrast to DR4 and DR5, decoy receptors do not signal apoptosis. DcR1/TRAIL-R is a glycosyl phosphatidylinositol (GPI)-anchored membrane protein and DcR2/TRAIL-R4 contains a truncated, nonfunctional death domain. In mice, mDcR1 is a GPI-anchored membrane protein, and mDcR2 can be expressed as two alternatively spliced variants, a secreted form (mDcR2S) and a transmembrane form (mDcR2L). It has recently been reported that the inhibitory mechanism by which DcR2 prevents DR5-mediated apoptosis is not generally due to competitive binding to TRAIL, but rather by DcR2 association with DR5, via preligand assembly domain interactions, to form a death-inhibitory complex (Clancy et al., 2005) . Thus, several mechanisms of inhibition may allow decoy receptors to prevent TRAIL-mediated apoptosis.
Targeting DR4/DR5 in cancer therapies TRAIL has been reported to preferentially induce apoptotic cell death in a wide variety of tumor cells and transformed cells, but not in most normal cells. Thus, recombinant TRAIL (rTRAIL) is an attractive anti cancer therapeutic. Preclinical studies in mice and non-human primates have shown that the administration of soluble forms of rTRAIL suppressed the growth of TRAIL-sensitive human tumor xenografts, with no apparent systemic toxicity (Ashkenazi et al., 1999; Walczak et al., 1999) , supporting the potential utility of rTRAIL in vivo. Clearly, according to their decoy receptor expression, some tumor cells expressing DR5 or DR4 may still be protected from rTRAIL-induced apoptosis. Furthermore, monoclonal antibodies (mAbs) generally have longer half-life in vivo than recombinant proteins. Thus, specific targeting of death-inducing TRAIL receptors (DR4 and/or DR5) by agonistic mAbs may theoretically be a more effective approach than using the recombinant TRAIL ligand. Alternatively, although cancer cells express DR5 and DR4 more preferentially than normal cells (Daniels et al., 2005) , anti-DR4 or anti-DR5 mAbs may be more toxic than rTRAIL, since the decoy receptors might protect DR4-and/or DR5-expressing normal cells from TRAILinducing killing (Sheridan et al., 1997; Degli-Esposti, 1999; Kim et al., 2000) . To date, it has been reported that agonistic anti-human DR4 or DR5 mAbs exhibited potent tumoricidal activities against human tumor xenografts in nude or SCID mice without apparent toxicity Chuntharapai et al., 2001; Ichikawa et al., 2001; Motoki et al., 2005; Pukac et al., 2005) . Either mAb possessing intrinsic agonistic activity or protoagonistic types of mAb requiring crosslinking of their Fc domains for agonistic activity show apoptosismediated tumoricidal activity in vivo. Interestingly, the tumoricidal activity of anti-human DR4 mAb in mice bearing human tumor xenografts was reported to be markedly influenced by their isotype, suggesting a critical contribution of Fc receptors on some effector functions in vivo (Chuntharapai et al., 2001) . In contrast to these observations, some human mAbs against human DR4 and DR5 induced apoptosis in cultured normal human hepatocytes in vitro (Mori et al., 2004) , reminiscent of the different cytotoxic activity of recombinant TRAIL against normal cells due to altered forms (Jo et al., 2000; Lawrence et al., 2001; Qin et al., 2001) . Thus, the nature of mAbs (epitope, affinity, isotype, etc.) and the status of normal cells may be Figure 2 TRAIL-induced apoptosis signaling pathway and resistant mechanisms. Trimerization of DR5 or DR4 by a TRAIL trimer leads to recruitment of the adaptor FADD, which in turn recruits and activate caspase 8. In certain cells (type I cells), activation of caspase 8 is sufficient for activation of caspase 3, which executes apoptosis (extrinsic pathway). In other cells (type II cells), amplification through the mitochondrial pathway is initiated by cleavage of Bid by caspase 8 and translocation of the truncated Bid to mitochondria. This leads to Bax/Bak-mediated release of cytochrome-c (cyt-c), and subsequent caspase 9 activation by Apaf-1, is then required for caspase 3-mediated apoptosis (intrinsic pathway). DcR1 and DcR2 can act as decoy receptors competing with DR4 and DR5 for TRAIL. FLIP can prevent the recruitment of caspase 8. Bcl-2 and Bcl-xL can suppress the Bax/Bak-mediated release of cyt-c and Smac/DIABLO from mitochondria. Inhibitor of apoptosis proteins (IAPs) can attenuate the activation of caspase 9 and caspase 3, although Smac/DIABLO can counteract IAPs. critical as to whether apoptosis is inducible in normal cells (hepatocytes, endothelial cells, dendritic cells (DCs), etc.), and thus these parameters should be further analysed to safely treat in a clinical setting.
Preclinical assessment of anti-DR5-mediated therapy
We have generated an agonistic hamster anti-mouse DR5-specific mAb (MD5-1) and examined the antitumor effects against syngeneic tumors in mice . This mAb induced apoptosis in TRAILsensitive tumor cells when crosslinked in vitro. All examined DR5-expressing TRAIL-resistant cell lines were resistant to anti-DR5 mAb-induced apoptosis. We also observed, using a large variety of tumor target cells, that the sensitivity to anti-DR5 mAb-induced apoptosis closely correlated with TRAIL-induced apoptosis. Thus, it would appear that mouse TRAIL decoy receptors only make a minor contribution to protecting tumor cell from TRAIL-mediated killing, a finding consistent with the observation in human tumor cells Zhang et al., 1999; LeBlanc and Ashkenazi, 2003) .
Anti-mouse DR5 (MD5-1) mAb exerted potent antitumor effects against TRAIL-sensitive tumor cells in vivo. Consistent with the requirement for crosslinking to induce apoptosis in vitro, Fc-receptor expressing innate immune cells, including macrophages and NK cells, were required for the antitumor effect of this mAb. The MD5-1-induced antitumor effect was demonstrated to depend mainly on direct apoptosis induction, rather than antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), as DR5-expressing and Fas-associated death domain (FADD)-like IL-1b-converting enzyme (FLICE) inhibitory protein (FLIP)-transfected apoptosis-resistant tumor cell variants were completely resistant to MD5-1 in vitro and in vivo. Interestingly, apoptosis was similarly induced by this anti-DR5 mAb after crosslinking with either negative or positive signaling Fc receptors in vitro; however, the antitumor effect of this mAb was significantly reduced in mice deficient for the activating Fc-receptor (FcR common g-deficient mice lacking Fc g RI and Fc g RIII) compared with activity in wild-type or inhibitory Fc-receptor-deficient mice (FcRIIB-deficient mice) in vivo. We observed recruitment of FcR-expressing innate immune cells, macrophages and DCs into the early tumor site in wild-type mice, but not in mice deficient for the activating Fc-receptors. Thus, we assume that crosslinking of anti-DR5 mAb by ubiquitously expressed inhibitory Fc receptors primarily triggers apoptosis of cancer cells conjugated with Fab portion of anti-DR5 mAb. At the same time, the binding of Fc portion of the mAb to an activating Fc receptor concurrently facilitates the recruitment additional Fc receptor-expressing cells to tumor site. This amplifies the number of effector cells capable of crosslinking anti-DR5 mAb in tumor site and augmenting tumor cell apoptosis. Macrophages are thought to normally suppress antitumor immunity and facilitate tumor growth (Pollard, 2004) ; however, they may be substantial effector cells that induce apoptosis following anti-DR5 mAb treatment. Thus, not only Fab-mediated tumor cell death but also Fc-mediated activation of innate immune cells infiltrating the tumor site may be key initial steps in the antitumor activity of anti-DR5 mAb. This activating Fc-receptor-mediated immune activation has been also revealed an advantage of antibody-based targeting therapy in other tumor-targeting mAb therapies (Clynes et al., 1998 (Clynes et al., , 2000 Zhang et al., 2004) .
Surprisingly, anti-DR5 mAb treatment was shown to eradicate small tumor burdens in mice and indeed concurrently generate tumor-specific cytolytic T lymphocytes (CTLs). Subsequent tumor challenge revealed that TRAIL-resistant tumor variants could be eliminated in a perforin-dependent manner. Induction of tumor-specific CTL required primary DR5-mediated tumor cell death, as CTL never developed when FLIPoverexpressing tumors were treated primarily. Hence, following anti-DR5 mAb treatment, the recruitment of Fc receptor-expressing professional antigen-presenting cells (APCs) into the tumor site resulted in the efficient induction of tumor-specific T cells (Figure 3) . Thus, anti-DR5 mAb may be more beneficial than rTRAIL for cancer therapy, as anti-DR5 mAb not only primarily eliminates most of the TRAIL-sensitive tumor cells at the time of administration but also secondarily induces tumor-specific effector and memory T cells that can eradicate TRAIL-resistant variants and provide a longterm protection from tumor recurrence. Undoubtedly, the emergence of TRAIL-resistant variants is a critical problem for mTRAIL-based therapy (LeBlanc et al., 2002) . Further experiments with other anti-DR5 mAb that do not require crosslinking to induce apoptosis, other isotypes of anti-DR5 mAb or mouse rTRAIL are essential to definitely prove that engagement of innate immunity is a critical feature of effective mAb-based therapy in this context.
Apoptosis in other mAb-based therapies that inhibit tumor growth
In the past decade, a number of tumor-targeting antibodies have been approved for cancer treatment. Multiple mechanisms, including ADCC, CDC, opsonisation and phagocytosis, have been reported to generally contribute to the antitumor effects of various tumor-targeting antibodies (Gelderman et al., 2004) . Apoptosis can be induced by growth factor withdrawal, and thus antibodies to growth signal-mediating receptors on tumor cells might in part act by inducing apoptosis in tumor cells. Epidermal growth factor receptors (EGFRs) are integral components of principal signaling cascades involved in regulating solid tumor cell proliferation and angiogenesis (de Bono and Rowinsky, 2002) . Therefore, EGFR blockade is a rational therapeutic approach to treat some malignancies (Salomon et al., 1995) . Anti-EGFR mAbs (Cetuximab, etc.) block ligand binding to the EGFR or dimerize and internalize EGFR, which results in inhibition of EGF-stimulated EGFR tyrosine kinase activity. Apoptosis is reported to contribute to the antitumor effect of anti-EGFR mAbs, although the major mechanism is thought to be cell cycle arrest in the G1 phase (Bianco et al., 2005) . Anti-CD20 mAb (Rituximab) has been clinically used to treat B-cell chronic lymphocytic leukemia and non-Hodgkin's lymphoma; although this mAb requires Fc receptor crosslinking and exhibits its antitumor effects through multiple mechanisms, it has also been reported to induce apoptosis (Cragg et al., 1999; Reed et al., 2002; Smith, 2003) . Anti-HER2 mAb specific for the cellular protooncogene p185HER2/neu (Carter et al., 1992; Pegram et al., 1998) was the first mAb approved for use in solid tumors and it has already developed clear therapeutic benefit in the clinical treatment of breast cancer. Some anti-HER2 mAb can induce apoptosis as well as inhibition of cell growth (Hinoda et al., 2004) . Thus, apoptosis of cancer cells is implicated as a common mechanism employed by a number of clinically useful antitumor antibodies.
One of the most obvious and important questions is whether mAb reactive with cell death-inducing receptors, which directly induce apoptosis, can prevent tumor growth more effectively than mAb targeting other types of molecules that both arrest cell proliferation and subsequently cause apoptosis in tumor cells. Our preliminary data suggest an improved antitumor efficacy of anti-DR5 mAb compared with an anti-rat HER2 mAb against rat HER2-expressing tumors derived from rat HER2-transgenic mice (Figure 4 ). Although further extensive comparative studies are required and should be validated in clinical settings, our observation suggests that anti-DR5 mAb therapy may be comparable to anti-Her2 mAb therapy against TRAIL-sensitive Her2-expressing tumor cells.
Combination therapies

Enhancing apoptosis
Most of the DNA-damaging chemotherapeutic drugs and radiation induce tumor cell apoptosis by triggering p53-mediated activation of the intrinsic pathway. As TRAIL-induced apoptosis is mediated through both the extrinsic and intrinsic pathways in a p53-independent (Albert et al., 1998; Dhodapkar et al., 2002; Rafiq et al., 2002; Akiyama et al., 2003) , which can lyse TRAIL-resistant variants in perforin-mediated manner in anti-DR5 mAb-treated tumor-bearing host (c).
Anti-TRAIL-R mAb in cancer therapy K Takeda et al manner (Johnstone et al., 2002) , it is possible that combination therapy of TRAIL with chemotherapeutic drugs or radiation may potentially deliver greater apoptosis signals in cancer and results in excellent antitumor efficacy. In concert, many previous studies have shown that combinations of rTRAIL, anti-DR5 mAb or anti-DR4 mAb with chemotherapeutic agents or irradiation additively or synergistically induced tumor cell apoptosis in vitro and in vivo (Sheikh et al., 1998; Ashkenazi et al., 1999; Gliniak and Le, 1999; Chinnaiyan et al., 2000; Takimoto and El-Deiry, 2000; Chuntharapai et al., 2001; LeBlanc et al., 2002; Wajant et al., 2002; Buchsbaum et al., 2003; Ohtsuka et al., 2003; Voelkel-Johnson, 2003; Shankar and Srivastava, 2004) . Combinations are particularly attractive when various cancers are naturally resistant to TRAIL, chemotherapy or radiation. However, the treatments for sensitizing tumor cells to TRAIL may also sensitize normal cells to TRAIL, underlining the need for particular caution with combination therapies.
Proteasome inhibitors are suggested to affect TRAILinduced apoptosis at many different levels including NF-kB-dependent and independent pathways (Sayers and Murphy, 2006) . Indeed, inhibition of the proteasome by bortezomib in combination with rTRAIL enhanced apoptosis of a variety of human tumor cell lines, as well as primary tumor cells, but not normal cells, in vitro (Mitsiades et al., 2001; An et al., 2003; Ganten et al., 2005) . Further experiments will hopefully provide evidence that the combination of a proteasome inhibitor and TRAIL or anti-DR5/DR4 mAb can suppress tumors in vivo without any unfavorable side effects.
Co-treatment of breast cancer cells with both interferon-g and retinoic acid resulted in synergistic levels of TRAIL expression that induced the death of heterogeneous cancer cells in a paracrine fashion (Clarke et al., 2004) . IFNs augment TRAIL sensitivity by modulating the death-inducing signal pathway (Varela et al., 2001; Chawla-Sarkar et al., 2003) , and not surprisingly the antitumor effect of rTRAIL, anti-DR5 mAb or anti-DR4 mAb was augmented by IFN (Merchant et al., 2004; Papageorgiou et al., 2004) . Cytokines or bacterial components that stimulate IFN production might also be favorable candidates in combination with TRAIL-receptor targeting therapy.
Increased knowledge of the molecular components of the apoptotic pathway has encouraged the development of more specific agents that can be combined with death receptor targeting therapy Li et al., 2004) .
Combination with other immunomodulators
It has been reported that tumor-specific T-cell responses critically contributed to successful antibody-based tumortargeting therapy that causes cell death through inhibition of growth signals and Fc receptor-mediated ADCC and/or CDC (Cragg et al., 1999; Clynes et al., 2000; Selenko et al., 2001; Trcka et al., 2002; zum Buschenfelde et al., 2002; Smith, 2003; Gelderman et al., 2004) . Agonistic anti-DR5 mAb triggered tumor cell death directly via caspase activation, but also secondarily evoked tumor-specific CTL that could also eliminate anti-DR5-resistant variants . Despite a variety of pathways of cell death induction by mAbs, both primary tumor cell death and secondary induction of tumor-specific T-cell immunity have been implicated in the successful antitumor effects of such mAbs. Thus, combining primary tumor cell death with T-cell activation may be a very attractive approach to augment the therapeutic effect of the anti-DR5 mAb and other mAb-based tumor targeting (Pardoll and Allison, 2004) .
Based on this hypothesis, we have combined anti-DR5 mAb treatment with agonistic anti-CD40 mAb and agonistic anti-CD137 (4-1BB) mAb treatments, and coined the combination 'trimAb'. Both CD40 and CD137 are members of the TNF receptor superfamily that do not have a death domain, but alternatively they contain homologous sequence motifs that mediate interaction with specific adaptors from the TNFRassociated factor (TRAF) family, thereby causing NF-kB and mitogen-activated protein kinase activation (Wallach et al., 1999; Croft, 2003a) . CD40-stimulated DC produce IL-12 that enhances NK cell and NKT cell activation, T helper type I responses and CTL induction. The administration of agonistic anti-CD40 mAb induces potent antitumor effects in vivo (Diehl et al., 1999; French et al., 1999; Sotomayor et al., 1999) . Triggering CD137 signaling is also reported to elicit robust antitumor immune responses in vivo (Melero et al., 1997; Watts, 2005) . This effect is largely attributed to CD137 signaling of tumor-specific T cells, enhancing their proliferation and cytotoxic activity, and preventing their activation-induced cell death and immune tolerance (Pollok et al., 1993; Shuford et al., 1997; Takahashi et al., 1999; Wilcox et al., 2002) . Additionally, it was reported that CD137 signaling induces the activation of NK cells and DC (Melero et al., 1998; Futagawa et al., 2002) . With trimAb therapy, we proposed that a sequence of events may occur as follows: (1) anti-DR5 mAb induces apoptosis in tumor cells, recruits innate immune cells into the tumor site and possibly augments antigen-presenting function via activating Fc-receptors; (2) anti-CD40 mAb augments APC function of antigenloaded DC and enables IL-12 production; (3) anti-CD137 mAb facilitates the induction, activation and survival of tumor-antigen specific CD8 þ T cells, and therefore tumor-specific CTL would be effectively induced. Indeed, trimAb promptly induced tumorspecific T cells in the draining lymph node and resulted in the complete rejection of established TRAIL-sensitive tumors (Uno et al., 2006) . Moreover, trimAb therapy could even induce complete regression of tumor masses containing 90% apoptosis-resistant variants. Efforts to replace anti-DR5 with TRAIL ligands in combination with anti-CD40 and anti-CD137 mAbs were comparably unsuccessful (data not shown). Thus, due to the ability of mAb to engage innate immunity and downstream immune responses, mAb-based death receptortargeting may have advantages in combinations with immunomodulators when compared with recombinant protein ligands.
Importantly, trimAb therapy also induced complete tumor rejection in a large proportion of mice bearing established MCA-induced sarcomas, despite the known heterogeneity of these tumors and their capacity to evade natural immunity (Basombrio, 1970; Khong and Restifo, 2002; Dunn et al., 2004) . This trimAb-induced rejection of MCA-initiated sarcomas was mediated by CD8 þ T cells, although it might be expected to be primarily triggered by apoptosis of TRAIL-sensitive variants that appear in the MCA-induced tumor mass Takeda et al., 2002) . The cytotoxicity mediated by CTL from individual mice that rejected tumors after therapy was variable and this might reflect the spectrum of tumor antigens expressed by such heterogeneous tumor cells developing, following MCA-induced oncogenic transformation. Tumor heterogeneity that develops during carcinogenesis and following natural immune selection (immunoediting) may cause many immunotherapeutics to fail (Khong and Restifo, 2002; Dunn et al., 2004) . Therefore, a great advantage of the trimAb therapy is that tumor antigens do not have to be defined for therapeutic application. Moreover, the trimAb therapy approach may concurrently induce a number of different CTL specificities against various tumor antigens expressed on developing heterogeneous tumors, and thus may be suitable for coping with the genetic instability of tumors ( Figure 5) .
We have also recently found that trimAb combined with CD4 þ T-cell activation using an agonistic anti-OX40 mAb may further augment the rejection frequency and allow rejection of larger tumor burdens Figure 5 Effector mechanisms of trimAb, a strategy combining apoptosis induction with immune activation. Anti-DR5 mAb induces apoptosis directly in tumor cells via crosslinking by FcgRs on innate immune cells including APCs. However, anti-DR5 mAb alone is not sufficient to induce strong tumor-specific immune responses capable of completely rejecting established tumors. Anti-CD40 mAb and anti-CD137 mAb, antibodies to co-stimulating TNF receptor superfamily members, cooperate to induce tumor-specific immune responses. These mAbs are less effective without a source of tumor antigen. In trimAb, both strategies complement one another. Anti-DR5 mAb induced apoptosis results in a rapid tumor antigen supply to FcgR-and CD40-activated APCs. These activated APCs promptly induce tumor-specific CTLs, and anti-CD137 mAb activates CTL responses and maintains CTL survival for long periods. The cooperation of these three mAbs results in rejection of a variety of established tumors by CTL utilizing perforin and IFN-g effector mechanisms. The predominant presentation of tumor antigens in the local draining lymph node may limit any potential autoimmunity and toxicity of this approach.
Anti-TRAIL-R mAb in cancer therapy K Takeda et al (data not shown). OX40 is another member of TNF receptor superfamily inducing CD4 þ T-cell activation (Croft, 2003b) , and has been reported to facilitate robust CD8 þ and CD4 þ T-cell responses against tumors (Lee et al., 2004) . Blockade of CTLA-4 mediated inhibitory signals to tumor-specific CD8 þ T cells and immune suppression by regulatory T cells is another interesting approach to further augment mAb-based antitumor effects (Egen et al., 2002) . We have also reported that IL-21 enhanced the induction of tumor-specific CTL by anti-DR5 mAb in mice (Smyth et al., 2006) . Thus, cytokines enhancing CTL expansion, effector function and/or survival are possibly favorable reagents to combine with antideath receptor therapy.
Clinical application
Consistent with the selective sensitivity of cancer cells to TRAIL-mediated apoptosis, augmented expression of DR5 and DR4 was reported in cancer cells, particularly in melanoma, lung cancer and gastrointestinal cancers (Daniels et al., 2005) . Sensitivity to rTRAIL-induced apoptosis was reported in cell lines derived from human colon, lung, breast, kidney, brain and skin cancer (Ashkenazi et al., 1999) . Till date, effective apoptosis induction by rTRAIL has been reported in human melanoma, leukemia, multiple myeloma, breast, bladder, prostate, renal or colon cancer in single treatments and/or combination therapy with chemotherapeutic agents (Chawla-Sarkar et al., 2002; An et al., 2003; Buchsbaum et al., 2003; van Geelen et al., 2003; VoelkelJohnson, 2003; Merchant et al., 2004; Georgakis et al., 2005; Kaufmann and Steensma, 2005; Kurbanov et al., 2005; Pukac et al., 2005; Bucur et al., 2006; Marini et al., 2006; O'Kane et al., 2006; Zeng et al., 2006) . Thus, these cancers are the most promising indications for clinical trials of TRAIL and anti-DR5/DR4 mAb.
Genentech Incorporated (South San Francisco, CA, USA) and Amgen (Thousand Oaks, CA, USA) are now undertaking phase I clinical trials with soluble recombinant human TRAIL in cancer patients and the results are greatly anticipated. Human Genome Sciences (HGS) in association with Cambridge Antibody Technologies are entering phase II trials with anti-DR4 mAb (HGS-ETR1) and further phase I trials with an anti-DR5 mAb (HGS-ETR2) in cancer patients are planned. In addition, a second anti-DR5 mAb (HGS-TR2J) developed by HGS in collaboration with the pharmaceutical division of the Kirin Brewery Company is in a phase I clinical trial (Rowinsky, 2005) .
Phase 1 trials have involved patients with advanced solid malignancies (and/or non-Hodgkins lymphomas in the case of the anti-DR4 mAb (HGS-ETR1)), antibody administration has been intravenous and dosing repeated every 14-28 days. A phase 1 study of anti-DR4 mAb (HGS-ETR1) in combination with gemcitabine and cisplatin has also been undertaken. To date, no major toxicities have been observed at least in response to the doses administered during these initial clinical trials, and it was reported that several patients with refractory or heavily pretreated disease have experienced stable disease during anti-DR5 mAb (HGS-ETR2) treatment (presentations at the AACR-NCI-EORTIC International Conference. Molecular Targets and Cancer Therapeutics, 2005). Although these early trials are promising, it is important to recognize that the utility of recombinant TRAIL and agonistic anti-DR5/DR4 Ab therapies is limited to patients with TRAIL-sensitive tumors. It is also obvious that TRAIL sensitivity will be various among individual cancer patients, even if preferential TRAIL-sensitivity and DR5/DR4 expression in certain cancer cell types were reported. The efficacy of DR5/DR4-targeting therapies will be improved dramatically, when diagnostic methods determining TRAIL sensitivity of clinically detectable human cancers are developed.
Possible side effects of TRAIL and anti-DR4/DR5 mAb
It is clear that the toxicity of therapy versus the efficacy of tumor treatment will be limiting in patients. As mentioned above, apoptosis induction in normal human cells (hepatocytes, keratinocytes, etc.) by some recombinant TRAIL, anti-DR5 mAb or anti-DR4 mAb was reported in vitro (Jo et al., 2000; Lawrence et al., 2001; Qin et al., 2001; Mori et al., 2004) . Thus, administration of recombinant TRAIL or anti-DR5/DR4 mAb might induce autoimmune type disorders due to direct cytotoxic activities toward normal cells. To date, no critical toxicities have been reported in any experimental setting, including hepatotoxicity (Hao et al., 2004) . As an exception, hepatotoxicity with elevated serum aspatate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin was reported in a few subjects when treated with higher doses (20 mg/kg) of anti-DR5 mAb (HGS-ETR2). Even if this unfavorable effect was observed only in a dose-limiting manner and using one anti-human DR5 mAb, the mechanisms underling hepatotoxicity should be revealed, since this will provide novel information for safer treatment with anti-DR5 mAb in humans in the future.
Alternatively, immature human and mouse DCs are sensitive to TRAIL-mediated apoptosis in vitro (Leverkus et al., 2000; Hayakawa et al., 2004) , and eliminated by TRAIL expressed on NK cells in vivo . Moreover, negative regulatory functions of DR5 on innate immune responses have been shown using TRAIL-receptor deficient mice (Diehl et al., 2004) . These reports suggested the possible immune suppressive effect of rTRAIL or anti-DR4/DR5 mAb treatments, which might result in an increased frequency of infectious disease during therapy. To date, there is no report showing severe immune suppression by TRAIL or anti-DR5/DR4 mAb treatments in any experimental settings and clinical trials. However, it may be even more important to monitor immune status during TRAIL or anti-DR5/DR4 mAb therapy, when combined with chemotherapies and/or radiotherapy.
Combination of antibody therapy in targeting different steps that collectively induce antitumor immunity is one of most rational strategies to eradicate established tumor masses. However, we clearly caution the use of such approaches given the immense power of immune system and attention must direct at assessing unfavorable side effects, including autoimmune reactions. Moreover, it has been noted that too much activation of immune responses occasionally results in various unfavorable side effects including hepatotoxicity (e.g. concanavalin A-induced hepatitis). Moreover, it has been reported that hepatocytes had augmented TRAIL sensitivity during viral infections, alcohol intake and cholestasis (Higuchi et al., 2002; Janssen et al., 2003; Mundt et al., 2003; Mundt et al., 2005) . Thus, disorders of hepatic function are the most expected side effects during DR5/DR4-targeting mono or combination therapy. Regardless, targeting TRAIL receptors will be relatively safer and more useful compared with cancer therapies that target other members of the deathinducing TNF receptor superfamily.
Conclusion and perspective
Evidence obtained in experimental mouse models clearly suggests that TRAIL is one of important immune effector molecules in the surveillance and elimination of developing tumors Takeda et al., 2002) . Besides, preferential resistance of tumor cells escaping immunity, termed 'immunoediting', might explain the failure of many immunotherapeutic approaches to cancer treatment (Dunn et al., 2004) . One might therefore expect that the TRAIL/TRAIL-R pathway would not be an effective target in cancer therapy. However, quite the contrary, preclinical data suggest the TRAIL-R might be a good target on tumor cells and many clinical trials using TRAIL receptorspecific mAbs are now in progress. Even if monotherapy with these antibodies is largely ineffective, it may still be possible to obtain significant therapeutic effects when combining these TRAIL-R reactive mAbs with other therapies (radiotherapy, chemotherapy and/or other mAb-based tumor targeting therapy). In particular, combination with immune activation therapy seems both logical and promising, given that antibodies naturally activate immune responses via Fc receptors. However, careful analysis of unfavorable side effects due to apoptosis induction in normal cells and over activation of immune responses will also be required in parallel to make sure these approaches are safe and effective.
Abbreviations ADCC, antibody-dependent cellular cytotoxicity; APCs, antigen-presenting cells; CDC, complement-dependent cytotoxicity; DCs, dendritic cells; EGFRs, epidermal growth factor receptors; mAbs, monoclonal antibodies; rTRAIL, recombinant TRAIL; TRAIL, TNF-related apoptosis-inducing ligand.
